Yemaachi Biotechnology

Why the Future of Oncology Depends on More Than Medicine By David Hutchful When most people think about advances in cancer care, they think about new drugs, new therapies, or breakthrough discoveries in biology. But increasingly, one of the most important

Yaw Bediako, PhD; Ireshyn Govender, PhD; and Nyasha Chambwe, PhD. Photo credit: AACR This year, Yemaachi Biotech was proud to participate in the American Association for Cancer Research (AACR) Annual Meeting in San Diego, one of the world's largest and mo

By Joyce Ngoi, Max Nwuba & Elikem Kisser Cancer samples collected in the form of Formalin-fixed paraffin-embedded (FFPE) tissue are most often the primary source for the characterisation of tumours. FFPE specimens are routinely obtained from patients duri

OneBio Venture Studio is proud to announce its second investment from Fund II into Yemaachi Biotech, a Ghana-based genomics company building the world's most diverse cancer bio-database to develop next-generation cancer drugs that work across diverse popu

Emmanuella Amoako, MD, MWACP, FGCP, was honored with the Pediatric Oncology Yvonne Award during the Yvonne Awards Ceremony at OncoDaily Party 2026, held on May 29 at Park West in Chicago. Natera was the exclusive partner of the Yvonne Awards Ceremony and

Abstract Background: Limited representation of African populations in cancer genomics constrains the clinical applicability of precision oncology. We describe the establishment and early outcomes of The African Cancer Atlas (TACA), a multi-site platform i

Abstract Background: Triple-negative breast cancer (TNBC) is disproportionately common among women of African ancestry and is associated with aggressive clinical behavior and limited therapeutic options. Understanding demographic and contextual determinan

At the laboratory of a genomics research company headquartered in Ghana's capital Accra, the low, steady whir of a whole-genome sequencer, calibrated to read the most intimate instructions of human life, is helping process cancer samples collected thousan

Yaw Bediako is an immunologist and the CEO of Yemaachi Biotech, an Accra-based immunogenomics company focused on diversifying precision oncology. Under his leadership, Yemaachi has positioned itself as a key contributor to African cancer research by lever

Ashesi University is pleased to welcome Dr. Yaw Bediako as the Dean of Research and Innovation. In this role, he will provide strategic leadership to advance our research initiatives, foster innovation across various academic disciplines, and strengthen p